(ABT:New York Consolidated)
Transactions by ABBOTT LABORATORIES (ABT) in the last 6 months
Bryan J. Kaminski, W.A. Peavy and Mariner Real Estate Management acquired Vacant Office Building in Las Colinas from Abbott Laboratories (NYSE:ABT) on August 13, 2015. Fults Commercial Real Estate has been hired to market the property. Tom Strohbehn and Scot C Farber with Cushman & Wakefield of Texas Inc brokered the sale. Mark West and Adam Herrin with Holliday Fenoglio Fowler provided investment advisory services.
Abbott Laboratories (NYSE:ABT) entered into an agreement to acquire the remaining 90% stake in Tendyne Holdings Inc. from Apple Tree Partners and others for $250 million in cash on July 30, 2015. The deal includes an upfront payment of $225 million and potential future payments of $25 million tied to regulatory milestones. In a separate transaction, Abbott has provided capital and secured an option to purchase Cephea Valve Technologies. Abbott already made a $25 million ...
Prelude Corporation agreed to acquire CynoGen Inc. from Abbott Laboratories (NYSE:ABT) on April 9, 2015. Jones Day acted as legal advisor for Abbott Laboratories.
|AstraZeneca PLC||4,072 GBp||+38.50|
|Biogen Inc||$292.50 USD||-4.80|
|Danaher Corp||$84.79 USD||-2.23|
|Eli Lilly & Co||$79.80 USD||-2.55|
|Thermo Fisher Scientific Inc||$121.45 USD||-3.92|
|View Industry Companies|